NCT07416188 2026-04-22
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
Clinical Trials
19 trialsNCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT02866747 2026-04-14
STERIMGLI
Institut Claudius Regaud
Phase 1/2 Completed
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT07185880 2026-04-14
STAR-GBM
Myosin Therapeutics Inc.
Phase 1/2 Recruiting
NCT04528680 2026-04-13
SC9/ABX
Northwestern University
Phase 1/2 Active not recruiting
NCT05432804 2026-04-13
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Suspended
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT03277638 2026-04-09
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Case Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT03596086 2026-03-30
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT03603405 2026-03-30
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT05765812 2026-03-30
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT07431216 2026-03-30
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Starlight Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT07501559 2026-03-30
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Jecho Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT04801147 2026-03-27
DENDR1
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 1/2 Completed
NCT02586857 2026-03-25
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Phase 1/2 Active not recruiting